

BRUKER BIOSCIENCES CORP
Form 10-Q
November 09, 2005

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

**QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2005

**TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

FOR THE TRANSITION PERIOD FROM TO

Commission File Number 000-30833

Bruker BioSciences Corporation

(Exact name of registrant as specified in its charter)

DELAWARE
(State or other jurisdiction of
incorporation or organization)

04-3110160
(I.R.S. Employer
Identification Number)

40 Manning Park

Billerica, MA 01821

(Address of principal executive offices)

(978) 663-3660

(Registrant's telephone number, including area code)

Indicate by checkmark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by checkmark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes No

Indicate by checkmark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2). Yes No

As of November 7, 2005, there were 89,498,976 shares of the Registrant's common stock outstanding.

Edgar Filing: BRUKER BIOSCIENCES CORP - Form 10-Q

Bruker BioSciences Corporation

Form 10-Q

For the Quarter Ended September 30, 2005

Index

PART I FINANCIAL INFORMATION

ITEM 1: Financial Statements:

Condensed Consolidated Balance Sheets as of September 30, 2005 and December 31, 2004

Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2005 and 2004

Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2005 and 2004

Notes to Condensed Consolidated Financial Statements

ITEM 2: Management's Discussion and Analysis of Financial Condition and Results of Operations

ITEM 3: Quantitative and Qualitative Disclosures about Market Risk

ITEM 4: Controls and Procedures

PART II OTHER INFORMATION

ITEM 1: Legal Proceedings

ITEM 2: Unregistered Sales of Equity Securities and Use of Proceeds

ITEM 3: Defaults Upon Senior Securities

ITEM 4: Submission of Matters to a Vote of Security Holders

ITEM 5: Other Information

ITEM 6: Exhibits

SIGNATURES

PART I FINANCIAL INFORMATION

ITEM 1: Financial Statements

Bruker BioSciences Corporation

Condensed Consolidated Balance Sheets

Edgar Filing: BRUKER BIOSCIENCES CORP - Form 10-Q

(in thousands, except share data)

| | September 30 2005 (Unaudited) | December 31, 2004 |
|--|-------------------------------------|----------------------|
| ASSETS | | |
| Current assets: | | |
| Cash, cash equivalents and short-term investments | \$ 95,337 | \$ 77,691 |
| Accounts receivable, net | 49,370 | 57,792 |
| Due from affiliated companies | 5,920 | 9,530 |
| Inventories | 99,309 | 107,748 |
| Other current assets | 13,103 | 18,530 |
| Total current assets | 263,039 | 271,291 |
| Property, plant and equipment, net | 73,472 | 84,990 |
| Intangibles and other assets | 14,835 | 15,266 |
| Total assets | \$ 351,346 | \$ 371,547 |
| LIABILITIES AND SHAREHOLDERS EQUITY | | |
| Current liabilities: | | |
| Short-term borrowings | \$ 10,960 | \$ 12,205 |
| Accounts payable | 14,804 | 22,652 |
| Due to affiliated companies | 2,857 | 3,026 |
| Customer advances | 25,254 | 21,045 |
| Other current liabilities | 54,816 | 52,232 |
| Total current liabilities | 108,691 | 111,160 |
| Long-term debt | 21,821 | 27,763 |
| Other long-term liabilities | 13,915 | 15,349 |
| Commitments and contingencies (Note 12) | | |
| Preferred stock, \$0.01 par value, 5,000,000 shares authorized, none issued or outstanding at September 30, 2005 or December 31, 2004 | | |
| Common stock, \$0.01 par value, 150,000,000 shares authorized, 89,479,039 and 89,470,714 shares issued and outstanding at September 30, 2005 and December 31, 2004, respectively | 895 | 895 |
| Other stockholders equity | 206,024 | 216,380 |
| Total shareholders equity | 206,919 | 217,275 |
| Total liabilities and shareholders equity | \$ 351,346 | \$ 371,547 |

See the accompanying notes to financial statements.

Bruker BioSciences Corporation

Condensed Consolidated Statements of Operations

(in thousands, except per share data)

(Unaudited)

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|--|-------------------------------------|--------------------|------------------------------------|--------------------|
| | 2005 | 2004 (Restated) | 2005 | 2004 (Restated) |
| Product revenue | \$ 61,061 | \$ 58,412 | \$ 188,609 | \$ 174,707 |
| Service revenue | 8,748 | 7,430 | 26,479 | 22,855 |
| Other revenue | 928 | 635 | 1,928 | 1,217 |
| Total revenue | 70,737 | 66,477 | 217,016 | 198,779 |
| Cost of product revenue | 35,452 | 32,960 | 107,992 | 103,815 |
| Cost of service revenue | 4,866 | 4,570 | 16,681 | 14,205 |
| Total cost of revenue | 40,318 | 37,530 | 124,673 | 118,020 |
| Gross Profit | 30,419 | 28,947 | 92,343 | 80,759 |
| Sales and marketing | 11,845 | 12,952 | 37,382 | 38,816 |
| General and administrative | 5,677 | 5,257 | 16,632 | 14,515 |
| Research and development | 9,969 | 10,824 | 31,951 | 31,091 |
| Total operating expenses | 27,491 | 29,033 | 85,965 | 84,422 |
| Operating income (loss) | 2,928 | (86) | 6,378 | (3,663) |
| Interest and other income (expense), net | 577 | (1,902) | 1,001 | (2,768) |
| Income (loss) before income tax provision and minority interest in consolidated subsidiaries | 3,505 | (1,988) | 7,379 | (6,431) |
| Income tax provision | 2,398 | 955 | 5,468 | 395 |
| Income (loss) before minority interest in consolidated subsidiaries | 1,107 | (2,943) | 1,911 | (6,826) |
| Minority interest in consolidated subsidiaries | 28 | 115 | 131 | 145 |
| Net income (loss) | \$ 1,079 | \$ (3,058) | \$ 1,780 | \$ (6,971) |
| Net income (loss) per common share - basic and diluted | \$ 0.01 | \$ (0.03) | \$ 0.02 | \$ (0.08) |
| Weighted average common shares outstanding: | | | | |
| Basic | 89,476 | 89,456 | 89,473 | 88,156 |
| Diluted | 89,669 | 89,456 | 89,620 | 88,156 |

See the accompanying notes to financial statements.

Bruker BioSciences Corporation

Condensed Consolidated Statements of Cash Flows

(in thousands)

(Unaudited)

| | Nine Months Ended September 30, | |
|--|------------------------------------|--------------------|
| | 2005 | 2004 (Restated) |
| Operating activities: | | |
| Net cash provided by (used in) operating activities | \$ 25,578 | \$ (10,482) |
| Investing activities: | | |
| Purchases of property and equipment | (2,172) | (3,867) |
| Purchases (redemptions) of short-term investments, net | 105 | (344) |
| Changes in restricted cash | (142) | |
| Net cash used in investing activities | (2,209) | (4,211) |
| Financing activities: | | |
| Proceeds from short-term borrowings, net | 272 | 6,012 |
| Repayments of long-term debt, net | (3,616) | (5,783) |
| Proceeds from issuance of common stock | 213 | 14,493 |
| Net cash provided by (used in) financing activities | (3,131) | 14,722 |
| Effect of exchange rate changes on cash | (2,592) | (250) |
| Net change in cash and cash equivalents | 17,646 | (221) |
| Cash, cash equivalents and short-term investments at beginning of period | 77,691 | 76,837 |
| Cash, cash equivalents and short-term investments at end of period | \$ 95,337 | \$ 76,616 |

See the accompanying notes to financial statements.

Bruker BioSciences Corporation

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. Description of Business and Basis of Presentation

Bruker BioSciences Corporation and its wholly-owned subsidiaries (the Company) design, manufacture, service and market proprietary life science systems based on mass spectrometry core technology platforms and X-ray technology. The Company also distributes products and sells a broad range of field analytical systems for nuclear, biological and chemical (NBC) detection. The Company maintains major technical centers in Europe, North America and Japan. The Company's diverse customer base includes pharmaceutical, biotechnology and proteomics companies, academic institutions, semiconductor industries and government agencies.

The financial statements represent the consolidated accounts of Bruker BioSciences Corporation and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated financial statements as of and for the three and nine months ended September 30, 2005 and 2004 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with Article 10 of Regulation S-X. The December 31, 2004 balance sheet is the balance sheet included in the audited financial statements as presented in the Company's 2004 Annual Report on Form 10-K. Accordingly, the financial information presented herein does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. The results for interim periods are not necessarily indicative of the results to be expected for the full year.

The Company reports financial results on the basis of two reportable segments; Bruker Daltonics and Bruker AXS. Bruker Daltonics is in the business of manufacturing and distributing mass spectrometry instruments that can be integrated and used along with other analytical instruments. Bruker AXS is primarily in the business of manufacturing and distributing advanced X-ray instrumentation used in non-destructive molecular and elemental analysis in academic, research and industrial applications.

For further information, refer to the consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2004.

2. Restatement of Financial Statements

The Company has restated its previously issued consolidated financial statements for the three and nine months ended September 30, 2004. Certain costs historically classified in sales and marketing and research and development expense were reclassified to cost of product revenue. For the three and nine months ended September 30, 2004, approximately \$2.1 million and \$6.6 million, respectively, related to the write-down of demonstration inventory to net realizable value was reclassified from sales and marketing and research and development expense to cost of product revenue. The Company also made changes to the consolidated financial statements for the three and nine months ended September 30, 2004 increasing cost of product revenue by \$0.3 million and \$0.6 million, respectively, for accounting corrections related primarily to inventory costing identified during the 2004 year-end closing process. The accounting corrections identified during the 2004 year-end closing process

impacted the Company's U.S. operations resulting in no tax effect being recognized on these adjustments.

3. Stock Compensation Arrangements

The Company measures compensation expense for its stock-based employee compensation plans using the intrinsic value method in accordance with Accounting Principles Board (APB) Opinion No. 25, Accounting for Stock Issued to Employees, and FASB Interpretation No. 44, Accounting for Certain Transactions Involving Stock Compensation. The Company has adopted the disclosure-only provisions of Statement of Financial Accounting Standards No. 148, Accounting for Stock-Based Compensation - Transition and Disclosure, an amendment of FASB Statement No. 123 (SFAS 148). Had compensation expense for the Company's stock option plans been determined based on the fair value at the grant date, consistent with the methodology prescribed by SFAS 148, the Company's net income (loss) and net income (loss) per common share for the three and nine months ended September 30, 2005 and 2004 would have approximated the following pro forma amounts (in thousands, except per share data):

Edgar Filing: BRUKER BIOSCIENCES CORP - Form 10-Q

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|--|-------------------------------------|------------|------------------------------------|------------|
| | 2005 | 2004 | 2005 | 2004 |
| Net income (loss), as reported | \$ 1,079 | \$ (3,058) | \$ 1,780 | \$ (6,971) |
| Deduct: | | | | |
| Total stock-based compensation expense determined using fair value based method for all awards, net of taxes | (641) | (615) | (1,917) | (1,845) |
| Net income (loss), pro forma | \$ 438 | \$ (3,673) | \$ (137) | \$ (8,816) |
| Net income (loss) per common share: | | | | |
| Basic and diluted, as reported | \$ 0.01 | \$ (0.03) | \$ 0.02 | \$ (0.08) |
| Basic and diluted, pro forma | \$ 0.00 | \$ (0.04) | \$ 0.00 | \$ (0.10) |

The fair value of each stock option included in the preceding pro forma amounts was estimated using the Black-Scholes option-pricing model with the following weighted average assumptions:

| | 2005 | 2004 |
|-------------------------|---------|---------|
| Risk-free interest rate | 3.83% | 3.63% |
| Expected life of option | 5 years | 5 years |
| Volatility | 67.7% | 71.5% |
| Expected dividend yield | 0% | 0% |

4. Inventories

Inventories consisted of the following as of September 30, 2005 and December 31, 2004 (in thousands):

| | September 30, 2005 | December 31, 2004 |
|---------------------|-----------------------|----------------------|
| Raw materials | \$ 27,695 | \$ 30,003 |
| Work-in-process | 30,894 | 36,799 |
| Demonstration units | 14,495 | 14,558 |
| Finished goods | 26,225 | 26,388 |
| Total inventories | \$ 99,309 | \$ 107,748 |

5. Goodwill and Other Intangible Assets

The following is a summary of other intangible assets subject to amortization as of September 30, 2005 and December 31, 2004 (in thousands):

| Useful Lives in Years | Gross Carrying Amount | September 30, 2005 | | December 31, 2004 | |
|-----------------------------|-----------------------------|-----------------------------|---------------------------|-----------------------------|---------------------------|
| | | Accumulated Amortization | Net Carrying Amount | Accumulated Amortization | Net Carrying Amount |

Edgar Filing: BRUKER BIOSCIENCES CORP - Form 10-Q

| | | | | | | | | | | | |
|---|----|----|-------|----|---------|----|-------|----|-------|----|-------|
| Existing technology and related patents | 4 | \$ | 1,520 | \$ | (855) | \$ | 665 | \$ | (570) | \$ | 950 |
| Customer relationships | 5 | | 310 | | (139) | | 171 | | (93) | | 217 |
| Trade names | 10 | | 310 | | (70) | | 240 | | (46) | | 264 |
| Total amortizable intangible assets | | \$ | 2,140 | \$ | (1,064) | \$ | 1,076 | \$ | (709) | \$ | 1,431 |

For each of the three and nine month periods ended September 30, 2005 and 2004, the Company recorded amortization expense of approximately \$0.1 million and \$0.4 million, respectively, related to other amortizable intangible assets.

The estimated future amortization expense related to other amortizable intangible assets is as follows (in thousands):

| For the year ending December 31, | (in thousands) | |
|----------------------------------|----------------|-------|
| 2005 (a) | \$ | 118 |
| 2006 | | 473 |
| 2007 | | 281 |
| 2008 | | 65 |
| 2009 | | 31 |
| Thereafter | | 108 |
| Total | \$ | 1,076 |

(a) Amount represents estimated amortization expense for the remaining three months ending December 31, 2005.

The carrying amount of goodwill as of September 30, 2005 and December 31, 2004 was \$10.7 million and is included in the Bruker AXS segment. The Company performs its annual test for indications of impairment as of December 31st each year. The Company completed its annual test for impairment as of December 31, 2004 and determined that goodwill was not impaired at that time.

6. Warranty Costs

The Company typically provides a one-year parts and labor warranty with the purchase of equipment. The anticipated cost for this one-year warranty is accrued upon recognition of the sale and is included as a current liability on the balance sheet. The Company also offers to its customers warranty and service agreements extending beyond the initial year of warranty for a fee. These fees are recorded as deferred revenue and amortized into income over the life of the extended warranty contract.

Changes in the Company's accrued warranty liability during the nine months ended September 30, 2005 were as follows (in thousands):

| | | |
|--|----|---------|
| Warranty accrual at December 31, 2004 | \$ | 8,052 |
| Accruals for warranties issued during the period | | 6,188 |
| Settlements of warranty claims | | (6,034) |
| Foreign currency impact | | (692) |
| Warranty accrual at September 30, 2005 | \$ | 7,514 |

7. Provision for Income Taxes

For the three and nine months ended September 30, 2005, the Company recorded an income tax provision of \$2.4 million and \$5.5 million, respectively, compared with an income tax provision of \$1.0 million and \$0.4 million, respectively, for the three and nine months ended September 30, 2004. In the United States, any income tax provision or benefit is currently recorded as an adjustment to the valuation allowance until sufficient positive evidence exists to support the reversal of a full valuation allowance which was established in 2003.

8. Employee Benefit Plans

The Company has a defined benefit retirement plan that covers substantially all employees of the Bruker AXS German subsidiary who were employed as of September 30, 1997. The plan provides pension benefits based upon final average salary and years of service.

The net periodic pension benefit cost includes the following components during the three and nine months ended September 30, 2005 and 2004 (in thousands):

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|--|-------------------------------------|--------|------------------------------------|--------|
| | 2005 | 2004 | 2005 | 2004 |
| Components of net periodic benefit cost | | | | |
| Service cost | \$ 154 | \$ 154 | \$ 480 | \$ 462 |
| Interest cost | 93 | 87 | 288 | 260 |
| Recognized actuarial loss | | | 197 | |
| Amortization | (9) | (15) | (23) | (45) |
| Net periodic benefit cost | \$ 238 | \$ 226 | \$ 942 | \$ 677 |

To date, the Company has not funded the defined benefit plan and is not required to make contributions during the remainder of 2005.

9. Earnings Per Share

Basic earnings per share is calculated by dividing net earnings (loss) by the weighted-average number of common shares outstanding during the period. Except where the result would be antidilutive, the diluted earnings per share computation includes the effect of shares which would be issuable upon the exercise of outstanding stock options, reduced by the number of shares which are assumed to be purchased by the Company from the resulting proceeds at the average market price during the period.

The following table sets forth the computation of basic and diluted average shares outstanding for the three and nine months ended September 30, 2005 and 2004 (in thousands):

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|---|-------------------------------------|------------|------------------------------------|------------|
| | 2005 | 2004 | 2005 | 2004 |
| Net income (loss), as reported | \$ 1,079 | \$ (3,058) | \$ 1,780 | \$ (6,971) |
| Weighted average shares outstanding: | | | | |
| Weighted average shares outstanding - basic | 89,476 | 89,456 | 89,473 | 88,156 |
| Net effect of dilutive stock options - based on treasury stock method | 193 | | 147 | |
| Weighted average shares outstanding - diluted | 89,669 | 89,456 | 89,620 | 88,156 |
| Net income (loss) per share - basic and diluted | \$ 0.01 | \$ (0.03) | \$ 0.02 | \$ (0.08) |

Stock options to purchase shares of common stock for the three and nine months ended September 30, 2004 were anti-dilutive and were excluded in the computation of diluted earnings per share due to the net losses for such periods.

10. Interest and Other Income (Expense), Net

The components of interest and other income (expense), net, were as follows for the three and nine months ended September 30, 2005 and 2004 (in thousands):

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|---|-------------------------------------|------------|------------------------------------|------------|
| | 2005 | 2004 | 2005 | 2004 |
| Interest income | \$ 1,007 | \$ 642 | \$ 2,472 | \$ 1,357 |
| Interest expense | (553) | (753) | (1,340) | (1,764) |
| Exchange gains (losses) on foreign currency transactions | 62 | (204) | (158) | (12) |
| Appreciation (depreciation) of the fair value of derivative financial instruments | 33 | 60 | 24 | (25) |
| Write-off of investments | | (1,647) | | (2,321) |
| Other income (expense) | 28 | | 3 | (3) |
| Interest and other income (expense), net | \$ 577 | \$ (1,902) | \$ 1,001 | \$ (2,768) |

11. Comprehensive Income (Loss)

Comprehensive income (loss) refers to revenues, expenses, gains and losses that under accounting principles generally accepted in the United States of America are included in other comprehensive income (loss), but excluded from net income (loss) as these amounts are recorded directly as an adjustment to stockholders' equity, net of tax. The following is a summary of comprehensive income (loss) for the three and nine months ended September 30, 2005 and 2004 (in thousands):

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|--|-------------------------------------|------------|------------------------------------|------------|
| | 2005 | 2004 | 2005 | 2004 |
| Net income (loss) | \$ 1,079 | \$ (3,058) | \$ 1,780 | \$ (6,971) |
| Foreign currency translation adjustments | (453) | 1,513 | (12,188) | (1,734) |
| Total comprehensive income (loss) | \$ 626 | \$ (1,545) | \$ (10,408) | \$ (8,705) |

12. Commitments and Contingencies

Lawsuits, claims and proceedings of a nature considered normal to its businesses may be pending from time to time against the Company. The Company believes the outcome of these proceedings, if any, will not have a material impact on the Company's financial position or results of operations.

13. Letters of Credit and Guarantees

As of September 30, 2005 and December 31, 2004, the Company had bank guarantees of \$6.8 million and \$7.3 million, respectively, for its customer advances. These bank guarantees affect the availability of the Company's lines of credit.

14. Business Segment Information

Edgar Filing: BRUKER BIOSCIENCES CORP - Form 10-Q

SFAS No. 131, Disclosures about Segments of an Enterprise and Related Information, (SFAS 131) establishes standards for reporting information about reportable segments in financial statements of public business enterprises. SFAS 131 also establishes standards for related disclosures about products and services, geographic areas and major customers. The Company reports financial results on the basis of two reportable segments: Bruker Daltonics and Bruker AXS. Bruker Daltonics manufactures and distributes mass spectrometry instruments that can be integrated and used along with other analytical instruments. Bruker AXS primarily manufactures and distributes advanced X-ray instrumentation used in non-destructive molecular and elemental analysis in academic, research and industrial applications. Bruker BioSciences Corporation, the parent company of Bruker Daltonics and Bruker AXS, is the corporate entity that holds excess cash and short-term investments and principally incurs certain public company costs.

Selected reportable segment financial information for the three and nine months ended September 30, 2005 and 2004 is presented below (in thousands):

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|---------------------------------|-------------------------------------|-----------|------------------------------------|------------|
| | 2005 | 2004 | 2005 | 2004 |
| Revenue: | | | | |
| Bruker Daltonics | \$ 36,949 | \$ 34,218 | \$ 116,954 | \$ 107,928 |
| Bruker AXS | 33,938 | 32,259 | 100,520 | 90,851 |
| Eliminations (a) | (150) | | (458) | |
| Total | \$ 70,737 | \$ 66,477 | \$ 217,016 | \$ 198,779 |
| Operating income (loss): | | | | |
| Bruker Daltonics | \$ 2,946 | \$ 1,531 | \$ 6,894 | \$ 1,783 |
| Bruker AXS | 594 | (775) | 1,835 | (3,541) |
| Corporate | (612) | (842) | (2,351) | (1,905) |
| Total | \$ 2,928 | \$ (86) | \$ 6,378 | \$ (3,663) |

(a) represents services revenue recorded on transactions between segments which is eliminated in consolidation.

15. Recent Accounting Pronouncements

In May 2005, the FASB issued SFAS No. 154, Accounting Changes and Error Corrections, a replacement of APB Opinion No. 20, Accounting Changes and FASB Statement No. 3, Reporting Accounting Changes in Interim Financial Statements (SFAS 154). SFAS 154 provides guidance on the accounting for and reporting of accounting changes and error corrections. It establishes, unless impracticable, retrospective application as the required method for reporting a change in accounting principle in the absence of explicit transition requirements specific to the newly adopted accounting principle. SFAS 154 also provides guidance for determining whether retrospective application of a change in accounting principle is impracticable and for reporting a change when retrospective application is impracticable. The provisions of this Statement are effective for accounting changes and corrections of errors made in fiscal periods beginning after December 15, 2005. The adoption of the provisions of SFAS 154 is not expected to have a material impact on the Company's financial position or results of operations.

In December 2004, the FASB issued SFAS No. 123 (Revised 2004) Share-Based Payment (SFAS No. 123R) that addresses the accounting for share-based payment transactions in which a Company receives employee services in exchange for (a) equity instruments of the Company or (b) liabilities that are based on the fair value of the Company's equity instruments or that may be settled by the issuance of such equity instruments. SFAS No. 123R addresses all forms of share-based payment awards, including shares issued under employee stock purchase plans, stock options, restricted stock and stock appreciation rights. SFAS No. 123R eliminates the ability to account for share-based compensation transactions using APB Opinion No. 25, Accounting for Stock Issued to Employees, that was provided in Statement 123 as originally issued. As permitted by SFAS No. 123R, the Company currently accounts for share-based payments to employees using the intrinsic value method allowed under APB Opinion 25 and, as such, generally recognizes no compensation cost for employee stock options. Accordingly, the adoption of SFAS No. 123R fair value method will have a significant impact the Company's results of operations, although it will have no impact on our overall financial position. The impact of adoption of SFAS No. 123R cannot be predicted at this time because it will depend on levels of share-based payments granted in the future. However, had we adopted SFAS No. 123R in prior periods, the impact would have approximated the amounts calculated using SFAS No. 123 as described in the disclosure of pro forma net income (loss) and net income (loss) per share in Note 3 to our consolidated financial statements.

16. Material Definitive Agreements

Edgar Filing: BRUKER BIOSCIENCES CORP - Form 10-Q

On August 13, 2005, the Company executed a binding agreement to acquire all the capital stock of SOCABIM SAS (SOCABIM), a privately-held Paris, France based company focused on advanced X-ray materials research and analysis software.

At the closing, the Company will pay approximately \$8.5 million of consideration comprised of (a) approximately \$7.2 million in cash, and (b) approximately \$1.3 million, which may, at the Company's discretion, be paid either in cash or by the issuance of restricted shares of Bruker BioSciences Corporation common stock to SOCABIM. In addition, there is the possibility of an earn-out in the amount of approximately \$1.9 million.

On October 10, 2005, the Company executed a binding agreement to acquire all of the capital stock of Röntec AG (Röntec), an X-ray analysis instrumentation company based in Berlin, Germany. At the closing, the Company will pay approximately \$1.8 million of cash to satisfy Röntec's outstanding debt and approximately \$3.7 million of consideration to Röntec's shareholders, of

which approximately \$0.9 million will be paid through the issuance of restricted shares of the Company's common stock and the remainder of which shall be paid in cash to Röntec's shareholders. Pursuant to the earn-out provisions of the agreement, up to approximately \$1.9 million of additional consideration, which will consist of a combination of 50% cash and 50% restricted shares, may be paid to Röntec's management, employee and consultant shareholders based on the 2006 and 2007 performance of Röntec. The Company also has an option to pay the earn-out 100% in cash.

On October 21, 2005, the Company executed a binding agreement to acquire the X-ray microanalysis business of Princeton Gamma-Tech Instruments, Inc. (PGT), which is based in Rocky Hill, New Jersey. At the closing, the Company will pay approximately \$1.9 million of consideration to PGT, of which \$0.4 million shall be held in escrow for twelve months pending the satisfaction of the non-competition and non-solicitation covenant in the agreement.

17. Subsequent Events

Accelerated Vesting of Unvested Stock Options

On October 3, 2005, the Compensation Committee of the Board of Directors of the Company approved the acceleration of vesting of all unvested options to purchase shares of common stock of the Company that are held by current employees, officers and directors of the Company, which have an exercise price per share equal to or greater than \$4.64 (the closing market price of the Company's common stock on October 3, 2005). Options to purchase 857,923 shares of common stock are subject to this acceleration, including 132,688 options held by officers and directors of the Company. Under the accounting for stock options in accordance with Accounting Principles Board Opinion No. 25 Accounting for Stock Issued to Employees, and FASB Interpretation No. 44 Accounting for Certain Transactions Involving Stock Compensation, the acceleration of the vesting of these options will not result in a compensation charge in the fourth quarter ending December 31, 2005 because the exercise prices of the affected options (which have not changed) is greater than the closing price of the Company's common stock on October 3, 2005.

Because these options have exercise prices in excess of current market values (are underwater), they are not fully achieving their original objectives of incentive compensation and employee retention. The Company believes that the acceleration of these underwater options may have a positive effect on employee morale and retention. The acceleration also reduces future compensation expense that the Company would otherwise recognize in its consolidated statement of operations with respect to these options once the Statement of Financial Accounting Standards No. 123 (revised 2004) Share-Based Payment, issued by the Financial Accounting Standards Board, becomes effective for reporting periods beginning in January 2006. Management has estimated the pre-tax charge to be eliminated from future accounting periods beginning in January 2006 amounts to approximately \$3.7 million over the original remaining vesting periods of the affected options.

ITEM 2: Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our financial condition and results of operations should be read in conjunction with our interim condensed consolidated financial statements and the notes to those statements included in Part 1, Item 1 of this Quarterly Report on Form 10-Q, and in conjunction with the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2004.

Statements contained in Management's Discussion and Analysis of Financial Condition and Results of Operations which express that we believe, anticipate, expect or plan to, as well as other statements which are not historical fact, are forward-looking statements within the meaning of the Private Securities Litigation Act of 1995. Actual events or results may differ materially from those set forth in forward-looking statements. Certain factors that might cause such a difference are discussed in Factors Affecting Our Business, Operating Results and Financial Condition set forth in our Annual Report on Form 10-K for the year ended December 31, 2004.

OVERVIEW

Bruker BioSciences

Bruker BioSciences Corporation and its wholly-owned subsidiaries (the Company) design, manufacture, service and market proprietary life science systems based on mass spectrometry core technology platforms and X-ray technology. The Company also distributes products and sells a broad range of field analytical systems for nuclear, biological and chemical (NBC) detection. The Company maintains major technical centers in Europe, North America and Japan. The Company's diverse customer base includes pharmaceutical, biotechnology and proteomics companies, academic institutions, semiconductor industries and government agencies. Our business strategy includes focusing on innovative product and solution development, while continuing to expand our global distribution and customer support capabilities.

The Company has restated its previously issued consolidated financial statements for the three and nine months ended September 30, 2004. Certain costs historically classified in sales and marketing and research and development expense were reclassified to cost of product revenue. For the three and nine months ended September 30, 2004, approximately \$2.1 million and \$6.6 million, respectively, related to the write-down of demonstration inventory to net realizable value was reclassified from sales and marketing and research and development expense to cost of product revenue. The Company also made changes to the consolidated financial statements for the three and nine months ended September 30, 2004 increasing cost of product revenue by \$0.3 million and \$0.6 million, respectively, for accounting corrections related primarily to inventory costing identified during the 2004 year-end closing process. The accounting corrections identified during the 2004 year-end closing process impacted the Company's U.S. operations and no tax effect was recognized on these adjustments.

For further information, refer to the consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2004.

The Company reports financial results on the basis of two reportable segments; Bruker Daltonics and Bruker AXS. Bruker Daltonics is in the business of manufacturing and distributing mass spectrometry instruments that can be integrated and used along with other analytical instruments. Bruker AXS is primarily in the business of manufacturing and distributing advanced X-ray instrumentation used in non-destructive

Edgar Filing: BRUKER BIOSCIENCES CORP - Form 10-Q

molecular and elemental analysis in academic, research and industrial and security applications.

The performance of the Bruker Daltonics business is dependent upon its products in life-science mass spectrometry and Nuclear, Biological and Chemical (NBC) detection. During the nine months ended September 30, 2005 revenues increased by 8.4% over the comparable period in 2004.

The analytical X-Ray performance of the Bruker AXS business is dependent upon its products in single crystal X-ray diffraction (SCD), polycrystalline X-ray diffraction (XRD) and X-ray fluorescence (XRF), as well as thermal analyzers. During the nine months ended September 30, 2005, revenues increased by 10.6% over the comparable period in 2004. In October 2005, Bruker AXS announced it entered into agreements to purchase Röntec AG and the x-ray microanalysis business of Princeton Gamma-Tech Instruments, Inc. These acquisitions are expected to close in the fourth quarter of 2005 and will be combined to form a new group within Bruker AXS which will focus on the X-ray microanalysis market, a market not previously addressed by Bruker AXS.

Our operating and net income has also improved during the nine months ended September 30, 2005 compared to the nine months ended September 30, 2004 as we continue to focus on becoming more profitable. We experienced improvements in overall gross

profit margins year-over-year, increasing from 40.3% during the nine months ended September 30, 2004 to 42.0% during the nine months ended September 30, 2005. These improvements are a result of our various ongoing gross margin improvement initiatives, as well as better capacity utilization on higher revenues. Our operating expenses as a percentage of revenue also decreased when comparing the nine months ended September 30, 2005 to the nine months ended September 30, 2004.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates and judgments, including those related to revenue recognition, allowance for doubtful accounts, inventories, goodwill, long-lived assets, warranty costs, income taxes, contingencies, and restructuring. We base our estimates and judgments on historical experience, current market and economic conditions, our observance of industry trends and other assumptions that we believe are reasonable and form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.

We believe the following critical accounting policies to be both those most important to the portrayal of our financial condition and those that require the most subjective judgment.

Revenue recognition. We recognize revenue from system sales when persuasive evidence of an arrangement exists, the price is fixed or determinable, title and risk of loss has been transferred to the customer and collectibility of the resulting receivable is reasonably assured. Title and risk of loss is generally transferred to the customer upon receipt of a signed customer acceptance form for a system that has been shipped, installed, and for which the customer has been trained. As a result, the timing of customer acceptance or readiness could cause our reported revenues to differ materially from expectations. When products are sold through an independent distributor, a strategic distribution partner or an unconsolidated affiliated distributor, which assumes responsibility for installation, we recognize the system sale when the product has been shipped and title and risk of loss has been transferred. Our distributors do not have price protection rights or rights to return; however, our products are warranted to be free from defect for a period of one year. For arrangements with multiple elements, we recognize revenue for each element based on the fair value of the element provided all other criteria for revenue recognition have been met. The fair value for each element provided in multiple element arrangements is typically determined by referencing historical pricing policies when the element is sold separately. Changes in our ability to establish the fair value for each element in multiple element arrangements could affect the timing of revenue recognition.

Revenue from accessories and parts is recognized upon shipment and service revenue is recognized as the services are performed.

Allowance for doubtful accounts. We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to pay amounts due. If the financial condition of our customers were to deteriorate, reducing their ability to make payments, additional allowances would be required, resulting in a charge to operations.

Inventories. Inventories are stated at the lower of cost or market, with cost determined by the first-in, first-out method. We maintain an allowance for excess and obsolete inventory to reflect the expected un-saleable or un-refundable inventory based on an evaluation of slow moving products. If ultimate usage or demand varies significantly from expected usage or demand, additional write-downs may be required, resulting in a charge to operations.

Goodwill, other intangible assets, investments in other companies, and other long-lived assets. We perform an evaluation of whether goodwill is impaired annually or when events occur or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Fair value is determined using market comparables for similar businesses or forecasts of discounted future cash flows. We also review other intangible assets, investments in other companies, and other long-lived assets when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. Should the fair value of our long-lived assets decline because of reduced operating performance, market declines, or other indicators of impairment, a charge to operations for impairment may be necessary.

Warranty costs. We normally provide a one-year parts and labor warranty with the purchase of equipment. The anticipated cost for this one-year warranty is accrued upon recognition of the sale and is included as a current liability on the balance sheet. Although our facilities undergo quality assurance and testing procedures throughout the production process, our warranty obligation is affected by product failure rates subsequent to initial installation and customer acceptance, material

usage and service delivery costs incurred in correcting a product failure. Although our actual warranty costs have historically been consistent with expectations, to the extent warranty claims activity or costs associated with servicing those claims differ from our estimates, revisions to the warranty accrual may be required.

Income taxes. We estimate the degree to which tax assets and loss carryforwards will result in a benefit based on expected profitability by tax jurisdiction, and provide a valuation allowance for tax assets and loss carryforwards that we believe will more likely than not go unused. If it becomes more likely than not that a tax asset or loss carryforward will be used for which a reserve has been provided, we reverse the related valuation allowance. If our actual future taxable income by tax jurisdiction differ from estimates, additional allowances or reversals of reserves may be necessary.

Contingencies. We estimate losses on contingencies and provide a reserve for these losses when the losses are probable and estimable. Should the ultimate losses on contingencies and litigation differ from estimates, adjustments to those reserves may be required.

Results of Operations

Three months ended September 30, 2005 compared to the three months ended September 30, 2004

The Company, as discussed above, has restated its previously issued consolidated financial statements for the three months ended September 30, 2004 for certain reclassifications and corrections of inventory-related costs. These adjustments are reflected in the following tables and discussions within Management's Discussion and Analysis of Financial Condition and Results of Operations.

Revenue

The following table presents revenue, change in revenue and revenue growth by reportable segment for the three months ended September 30, 2005 and 2004 (dollars in thousands):

| | 2005 | 2004 | \$ Change | Percentage Change |
|------------------|-----------|-----------|-----------|-------------------|
| Bruker Daltonics | \$ 36,949 | \$ 34,218 | \$ 2,731 | 8.0% |
| Bruker AXS | 33,938 | 32,259 | 1,679 | 5.2% |
| Eliminations (a) | (150) | | (150) | |
| Total Revenue | \$ 70,737 | \$ 66,477 | \$ 4,260 | 6.4% |

(a) represents service revenue recorded on transactions between segments which is eliminated in consolidation.

Bruker Daltonics revenue increased by \$2.7 million, or 8.0%, to \$36.9 million for the three months ended September 30, 2005 compared to \$34.2 million for the comparable period in 2004. Included in this change in revenue is approximately \$0.4 million from the impact of foreign exchange. Excluding the effect of foreign exchange, revenue increased by 7.0%. The increase in revenue excluding the effect of foreign exchange is a result of an increase in the number of life science systems sold period-over-period, partially offset by pricing pressures due to increased competition, and an increase in aftermarket revenue, which consists primarily of consumables, accessories, training and service primarily due to an increase in service revenue. Revenue associated with NBC detection systems was relatively flat year-over-year, but decreased as a percentage of product and service revenue. Included in other revenue for the three months ended September 30, 2005 and 2004 are grant revenues from various projects for early-stage research and development projects funded by the German government. This revenue reflects the impact of revised government rates published by the German government in the third quarter of 2005. Life science systems, NBC detection systems and aftermarket revenue as a percentage of Bruker Daltonics product and service revenue were as follows during the three months ended September 30, 2005 and 2004:

| | 2005 | | 2004 | |
|------------------------------|-----------|---|-----------|---|
| | Revenue | Percentage of Segment Product and Service Revenue | Revenue | Percentage of Segment Product and Service Revenue |
| Life Science Systems | \$ 26,580 | 73.8% | \$ 24,799 | 73.8% |
| NBC Detection Systems | 2,287 | 6.3% | 2,403 | 7.2% |
| Bruker Daltonics Aftermarket | 7,154 | 19.9% | 6,382 | 19.0% |
| Product and Service Revenue | 36,021 | 100% | 33,584 | 100% |
| Grant Revenue | 928 | | 634 | |
| Total Revenue | \$ 36,949 | | \$ 34,218 | |

Bruker AXS revenue increased by \$1.7 million, or 5.2%, to \$33.9 million for the three months ended September 30, 2005 compared to \$32.3 million for the comparable period in 2004. Included in this change in revenue is approximately \$0.1 million from the impact of foreign exchange. Excluding the effect of foreign exchange, revenue increased by 4.9%. The increase in revenue excluding the effect of foreign exchange is attributable to growth in our materials research systems and other systems revenue, and continued strong aftermarket revenue, partially offset by decreases in life science and elemental composition systems revenue. Other system revenue relates primarily to the distribution of products not manufactured by Bruker AXS. X-ray systems, other systems and aftermarket revenue as a percentage of Bruker AXS product and service revenue were as follows during the three months ended September 30, 2005 and 2004:

| | 2005 | | 2004 | |
|-----------------------------------|-----------|---|-----------|---|
| | Revenue | Percentage of Segment Product and Service Revenue | Revenue | Percentage of Segment Product and Service Revenue |
| X-Ray Systems | \$ 23,072 | 68.0% | \$ 23,746 | 73.6% |
| Other System Revenue | 2,290 | 6.7% | 1,043 | 3.2% |
| Bruker AXS Aftermarket | 8,576 | 25.3% | 7,470 | 23.2% |
| Total Product and Service Revenue | \$ 33,938 | 100% | \$ 32,259 | 100% |

Cost of Revenue

The following table presents cost of product and service revenue and gross profit margins on product and service revenue by reportable segment for the three months ended September 30, 2005 and 2004 (dollars in thousands):

| | 2005 | | 2004 | |
|-----------------------|-----------------|---------------------|-----------------|---------------------|
| | Cost of Revenue | Gross Profit Margin | Cost of Revenue | Gross Profit Margin |
| Bruker Daltonics | \$ 19,434 | 46.0% | \$ 17,251 | 48.6% |
| Bruker AXS | 21,034 | 38.0% | 20,279 | 37.1% |
| Eliminations (a) | (150) | | | |
| Total Cost of Revenue | \$ 40,318 | 42.2% | \$ 37,530 | 43.0% |

(a) represents the cost of services provided between segments which is eliminated in consolidation.

Bruker Daltonics cost of product and service revenue for the three months ended September 30, 2005 was \$19.4 million, resulting in a gross profit margin of 46.0%, compared to cost of product and service revenue of \$17.3 million, or a gross profit margin of 48.6% for the comparable period in 2004. The decrease in gross profit margin is attributable to the combination of pricing pressures due to increased competition and a favorable product mix in the third quarter of 2004 compared to 2005, partially offset by gross profit margin improvements related to various ongoing gross profit margin improvement programs and better capacity utilization as a result of increased revenue period-over-period.

Bruker AXS cost of product and service revenue for the three months ended September 30, 2005 was \$21.0 million, resulting in a gross profit margin of 38.0%, compared to cost of product and service revenue of \$20.3 million, or a gross profit margin of 37.1% for the

comparable period in 2004. The increase in gross profit margin is primarily attributable to various ongoing gross profit margin improvement programs, reduced warranty expenses as improvements continue to be made on the products introduced during 2004 and 2005 and better capacity utilization as a result of increased revenue period-over-period, partially offset by an increase in inventory reserves during the third quarter of 2005.

Sales and Marketing

The following table presents sales and marketing expense and sales and marketing expense as a percentage of product and service revenue by reportable segment for the three months ended September 30, 2005 and 2004 (dollars in thousands):

| | 2005 | | 2004 | |
|---------------------------|------------------------|--|------------------------|--|
| | Sales and Marketing | Percentage of Segment Product and Service Revenue | Sales and Marketing | Percentage of Segment Product and Service Revenue |
| Bruker Daltonics | \$ 5,582 | 15.5% | \$ 6,380 | 19.0% |
| Bruker AXS | 6,263 | 18.5% | 6,572 | 20.4% |
| Total Sales and Marketing | \$ 11,845 | 17.0% | \$ 12,952 | 19.7% |

Bruker Daltonics sales and marketing expense for the three months ended September 30, 2005 decreased to \$5.6 million, or 15.5% of product and service revenue, from \$6.4 million, or 19.0% of product and service revenue for the comparable period in 2004. The decrease in sales and marketing expense as a percentage of product and service revenue is primarily attributable to increased revenue in the third quarter of 2005 as compared to the third quarter of 2004 and to benefits realized from cost control initiatives announced during the second half of 2004, partially offset by increased commissions on higher revenues year-over-year.

Bruker AXS sales and marketing expense for the three months ended September 30, 2005 decreased to \$6.3 million, or 18.5% of product and service revenue, from \$6.6 million, or 20.4% of product and service revenue for the comparable period in 2004. The decrease in sales and marketing expense as a percentage of product and service revenue is primarily attributable to increased revenue in the third quarter of 2005 as compared to the third quarter of 2004 and to benefits realized from cost control initiatives announced during the second half of 2004, partially offset by increased commissions on higher revenues year-over-year.

General and Administrative

The following table presents general and administrative expense and general and administrative expense as a percentage of product and service revenue by reportable segment for the three months ended September 30, 2005 and 2004 (dollars in thousands):

Edgar Filing: BRUKER BIOSCIENCES CORP - Form 10-Q

| | 2005 | | 2004 | |
|----------------------------------|-------------------------------|--|-------------------------------|--|
| | General and Administrative | Percentage of Segment Product and Service Revenue | General and Administrative | Percentage of Segment Product and Service Revenue |
| Bruker Daltonics | \$ 2,285 | 6.3% | \$ 1,804 | 5.4% |
| Bruker AXS | 2,780 | 8.2% | 2,611 | 8.1% |
| Corporate | 612 | | 842 | |
| Total General and Administrative | \$ 5,677 | 8.1% | \$ 5,257 | 8.0% |

Bruker Daltonics' general and administrative expense for the three months ended September 30, 2005 increased to \$2.3 million, or 6.3% of product and service revenue, from \$1.8 million, or 5.4% of product and service revenue for the comparable period in 2004. The increase in general and administrative expenses as a percentage of product and service revenue is primarily due to increased professional service fees associated with audit and Sarbanes-Oxley requirements, and an increase in bad debt reserves during the third quarter of 2005.

Bruker AXS' general and administrative expenses for the three months ended September 30, 2005 increased to \$2.8 million, or 8.2% of product and service revenue, from \$2.6 million, or 8.1% of product and service revenue for the comparable period in 2004. The increase in general and administrative expenses as a percentage of product and service revenue is primarily due to increased professional service fees associated with audit and Sarbanes-Oxley requirements and certain professional fees incurred during the third quarter of 2005 associated with increased business development activities.

Corporate general and administrative expense for the three months ended September 30, 2005 decreased to \$0.6 million from \$0.8 million for the comparable period in 2004. Corporate general and administrative expenses represent expenses associated with being a public company not allocated to our reportable segments, including legal fees, audit and consulting fees and filing fees. The decrease in expenses is primarily attributable to certain accounting, audit and consulting fees recorded within corporate during the three months ended September 30, 2004 now being allocated to our reportable segments.

Research and Development

The following table presents research and development expense and research and development expense as a percentage of product and service revenue by reportable segment for the three months ended September 30, 2005 and 2004 (dollars in thousands):

| | 2005 | | 2004 | |
|--------------------------------|-----------------------------|--|-----------------------------|--|
| | Research and Development | Percentage of Segment Product and Service Revenue | Research and Development | Percentage of Segment Product and Service Revenue |
| Bruker Daltonics | \$ 6,703 | 18.6% | \$ 7,253 | 21.6% |
| Bruker AXS | 3,266 | 9.6% | 3,571 | 11.1% |
| Total Research and Development | \$ 9,969 | 14.3% | \$ 10,824 | 16.4% |

Bruker Daltonics research and development expense for the three months ended September 30, 2005 decreased to \$6.7 million, or 18.6% of product and service revenue, from \$7.3 million, or 21.6% of product and service revenue for the comparable period in 2004. The decrease in research and development expense is primarily attributable to benefits realized from cost control initiatives announced during the second half of 2004 and to a decrease in material purchases during the third quarter of 2005 compared to the third quarter of 2004.

Bruker AXS research and development expense for the three months ended September 30, 2005 decreased to \$3.3 million, or 9.6% of product and service revenue, from \$3.6 million, or 11.1% of product and service revenue for the comparable period in 2004. The decrease in research and development expense is primarily related cost control initiatives announced during the second half of 2004 and a decrease in external consulting services utilized during the third quarter of 2005 compared to the third quarter of 2004.

Interest and Other Income (Expense), Net

Interest and other income (expense), net, during the three months ended September 30, 2005 was \$0.6 million compared to (\$1.9) million during the comparable period in 2004. During the three months ended September 30, 2005, the major component within interest and other income (expense), net, was net interest income of \$0.5 million. During the three months ended September 30, 2004, the major components within interest and other income (expense), net, were the write-off an investment in the amount of (\$1.6) million, losses on foreign currency transactions of (\$0.2) million and net interest expense of (\$0.1) million.

Provision for Income Taxes

The income tax provision for the three months ended September 30, 2005 was \$2.4 million compared to an income tax provision of \$1.0 million for the comparable period in 2004. During the third quarter of 2005 and 2004, our effective tax rate was approximately 68% and (48%), respectively, and reflects our tax provision for non-U.S. entities only since no benefit was recognized for losses incurred in the U.S. We will maintain a full valuation allowance for our U.S. net operating losses until such evidence exists that it is more likely than not that the loss carry forward amounts will be utilized to offset U.S. taxable income. Our tax rate may change over time as the amount or mix of income and taxes outside the U.S. changes. Our effective tax rate is calculated using our projected annual pre-tax income or loss and is affected by research and development tax credits, the expected level of other tax benefits, the impact of changes to the valuation allowance as well as changes in the mix of our pre-tax income and losses among jurisdictions with varying statutory tax rates and credits.

Minority Interest in Consolidated Subsidiaries

Minority interest in consolidated subsidiaries for the three months ended September 30, 2005 was \$28,000 compared to \$0.1 million in the comparable period of 2004. The minority interest in subsidiaries represents the minority shareholders' proportionate share of net income of those subsidiaries for the three months ended September 30, 2005 and 2004. For the three months ended

Edgar Filing: BRUKER BIOSCIENCES CORP - Form 10-Q

September 30, 2005 and 2004, the minority interest relates to our two majority-owned subsidiaries, Incoatec GmbH and Baltic Scientific Instruments Ltd.

Nine months ended September 30, 2005 compared to the nine months ended September 30, 2004

The Company, as discussed above, has restated its previously issued consolidated financial statements for the nine months ended September 30, 2004. These adjustments are reflected in the following tables and discussions within Management's Discussion and Analysis of Financial Condition and Results of Operations.

Revenue

The following table presents revenue, change in revenue and revenue growth by reportable segment for the nine months ended September 30, 2005 and 2004 (dollars in thousands):

| | 2005 | | 2004 | | \$ Change | Percentage Change |
|------------------|------|---------|------|---------|-----------|-------------------|
| Bruker Daltonics | \$ | 116,954 | \$ | 107,928 | \$ 9,026 | 8.4% |
| Bruker AXS | | 100,520 | | 90,851 | 9,669 | 10.6% |
| Eliminations (a) | | (458) | | | (458) | |
| Total Revenue | \$ | 217,016 | \$ | 198,779 | \$ 18,237 | 9.2% |

(a) represents service revenue recorded on transactions between segments which are eliminated in consolidation.

Bruker Daltonics' revenue increased by \$9.0 million, or 8.4%, to \$117.0 million for the nine months ended September 30, 2005 compared to \$107.9 million for the comparable period in 2004. Included in this change in revenue is approximately \$2.9 million from the impact of foreign exchange. Excluding the effect of foreign exchange, revenue increased by 5.6%. The increase in revenue excluding the effect of foreign exchange is a result of an increase in the number of life science and NBC detection systems sold period-over-period and increased aftermarket revenue, partially offset by pricing pressures due to increased competition. Revenues for the nine months ended September 30, 2005 and 2004 include grant revenues from various projects for early-stage research and development projects funded by the German government. Life science systems, NBC detection systems and aftermarket revenue as a percentage of Bruker Daltonics' product and service revenue were as follows during the nine months ended September 30, 2005 and 2004:

| | 2005 | | 2004 | |
|----------------------|-----------|---|-----------|---|
| | Revenue | Percentage of Segment Product and Service Revenue | Revenue | Percentage of Segment Product and Service Revenue |
| Life Science Systems | \$ 81,243 | 70.6% | \$ 77,275 | 72.4% |

Edgar Filing: BRUKER BIOSCIENCES CORP - Form 10-Q

| | | | | |
|------------------------------|------------|-------|------------|-------|
| NBC Detection Systems | 10,962 | 9.5% | 8,804 | 8.3% |
| Bruker Daltonics Aftermarket | 22,821 | 19.9% | 20,632 | 19.3% |
| Product and Service Revenue | 115,026 | 100% | 106,711 | 100% |
| Grant Revenue | 1,928 | | 634 | |
| Total Revenue | \$ 116,954 | | \$ 107,345 | |

Bruker AXS revenue increased by \$9.7 million, or 10.6%, to \$100.5 million for the nine months ended September 30, 2005 compared to \$90.9 million for the comparable period in 2004. Included in this change in revenue is approximately \$2.3 million from the impact of foreign exchange. Excluding the effect of foreign exchange, revenue increased by 8.1%. The increase in revenue excluding the effect of foreign exchange is attributable to growth in our materials research systems and other systems revenue, and continued strong aftermarket revenue, partially offset by declines in life science and elemental composition systems revenue. Other system revenue relates primarily to the distribution of products not manufactured by Bruker AXS. X-ray systems, other systems and aftermarket revenue as a percentage of Bruker AXS product and service revenue were as follows during the nine months ended September 30, 2005 and 2004:

| | 2005 | | 2004 | |
|-----------------------------------|------------|---|-----------|---|
| | Revenue | Percentage of Segment Product and Service Revenue | Revenue | Percentage of Segment Product and Service Revenue |
| X-Ray Systems | \$ 70,669 | 70.3% | \$ 65,307 | 71.9% |
| Other System Revenue | 4,415 | 4.4% | 1,679 | 1.8% |
| Bruker AXS Aftermarket | 25,436 | 25.3% | 23,865 | 26.3% |
| Total Product and Service Revenue | \$ 100,520 | 100% | \$ 90,851 | 100% |

Cost of Revenue

The following table presents cost of product and service revenue and gross profit margins on product and service revenue by reportable segment for the nine months ended September 30, 2005 and 2004 (dollars in thousands):

| | 2005 | | 2004 | |
|-----------------------|-----------------|---------------------|-----------------|---------------------|
| | Cost of Revenue | Gross Profit Margin | Cost of Revenue | Gross Profit Margin |
| Bruker Daltonics | \$ 64,952 | 43.5% | \$ 60,894 | 42.9% |
| Bruker AXS | 60,179 | 40.1% | 57,126 | 37.1% |
| Eliminations (a) | (458) | | | |
| Total Cost of Revenue | \$ 124,673 | 42.0% | \$ 118,020 | 40.3% |

(a) represents service revenue recorded on transactions between segments which are eliminated in consolidation.

Bruker Daltonics cost of product and service revenue for the nine months ended September 30, 2005 was \$65.0 million, or a gross profit margin of 43.5%, compared to cost of product and service revenue of \$60.9 million, or a gross profit margin of 42.9% for the comparable period in 2004. The increase in gross profit margins is primarily attributable to various ongoing gross profit margin improvement programs and better capacity utilization as a result of increased revenues period-over-period, partially offset by pricing pressures due to increased competition.

Bruker AXS cost of product and service revenue for the nine months ended September 30, 2005 was \$60.2 million, or a gross profit margin of 40.1%, compared to cost of product and service revenue of \$57.1 million, or a gross profit margin of 37.1% for the comparable period in 2004. The increase in gross profit margins is primarily attributable to various ongoing gross profit margin improvement programs and reduced warranty expenses as improvements continue to be made on the products introduced during 2004 and 2005, partially offset by the lower margins derived from other system revenues, which increased period-over-period.

Sales and Marketing

The following table presents sales and marketing expense and sales and marketing expense as a percentage of product and service revenue by reportable segment for the nine months ended September 30, 2005 and 2004 (dollars in thousands):

Edgar Filing: BRUKER BIOSCIENCES CORP - Form 10-Q

| | 2005 | | 2004 | |
|---------------------------|------------------------|--|------------------------|--|
| | Sales and Marketing | Percentage of Segment Product and Service Revenue | Sales and Marketing | Percentage of Segment Product and Service Revenue |
| Bruker Daltonics | \$ 17,404 | 15.1% | \$ 18,209 | 17.1% |
| Bruker AXS | 19,978 | 19.9% | 20,607 | 22.7% |
| Total Sales and Marketing | \$ 37,382 | 17.4% | \$ 38,816 | 19.6% |

Bruker Daltonics sales and marketing expense for the nine months ended September 30, 2005 decreased to \$17.4 million, or 15.1% of product and service revenue, from \$18.2 million, or 17.1% of product and service revenue for the comparable period in 2004. The decrease in sales and marketing expense as a percentage of product and service revenue is primarily attributable to increased revenue during the nine months ended September 30, 2005 compared to the comparable period in 2004 and to benefits realized from cost

control initiatives announced during the second half of 2004, partially offset by increased commissions on higher revenues year-over-year.

Bruker AXS sales and marketing expense for the nine months ended September 30, 2005 decreased to \$20.0 million, or 19.9% of product and service revenue, from \$20.6 million, or 22.7% of product and service revenue for the comparable period in 2004. The decrease in sales and marketing expense as a percentage of product and service revenue is primarily attributable to increased revenue during the nine months ended September 30, 2005 as compared to the nine months ended September 30, 2004 and to benefits realized from cost control initiatives announced during the second half of 2004, partially offset by increased commissions on higher revenues year-over-year.

General and Administrative

The following table presents general and administrative expense and general and administrative expense as a percentage of product and service revenue by reportable segment for the nine months ended September 30, 2005 and 2004 (dollars in thousands):

| | 2005 | | 2004 | |
|----------------------------------|-------------------------------|--|-------------------------------|--|
| | General and Administrative | Percentage of Segment Product and Service Revenue | General and Administrative | Percentage of Segment Product and Service Revenue |
| Bruker Daltonics | \$ 6,603 | 5.7% | \$ 5,534 | 5.2% |
| Bruker AXS | 7,678 | 7.6% | 7,075 | 7.8% |
| Corporate | 2,351 | | 1,906 | |
| Total General and Administrative | \$ 16,632 | 7.7% | \$ 14,515 | 7.3% |

Bruker Daltonics general and administrative expense for the nine months ended September 30, 2005 increased to \$6.6 million, or 5.7% of product and service revenue, from \$5.5 million, or 5.2% of product and service revenue for the comparable period in 2004. The increase in general and administrative expenses as a percentage of product and service revenue is primarily due to increased professional service fees associated with audit and Sarbanes-Oxley requirements, and an increase in bad debt reserves during the nine months ended September 30, 2005.

Bruker AXS general and administrative expense for the nine months ended September 30, 2005 increased to \$7.7 million, or 7.6% of product and service revenue, from \$7.1 million, or 7.8% of product and service revenue for the comparable period in 2004. The decrease in general and administrative expenses as a percentage of product and service revenue is primarily attributable to increased revenue during the nine months ended September 30, 2005 as compared to the nine months ended September 30, 2004 and to cost control initiatives announced during the second half of 2004, partially offset by increased professional service fees associated with audit and Sarbanes-Oxley requirements.

Corporate general and administrative expense for the nine months ended September 30, 2005 increased to \$2.4 million from \$1.9 million for the comparable period in 2004. Corporate general and administrative expenses represent expenses associated with being a public company not allocated to our reportable segments, including legal fees, audit and consulting fees and filing fees. The increase in expenses is primarily

Edgar Filing: BRUKER BIOSCIENCES CORP - Form 10-Q

attributable to increased professional service fees associated with audit and Sarbanes-Oxley requirements, partially offset by certain accounting, audit and consulting fees classified as corporate expenses during the nine months ended September 30, 2004 now being allocated to our reportable segments.

Research and Development

The following table presents research and development expense and research and development expense as a percentage of product and service revenue by reportable segment for the nine months ended September 30, 2005 and 2004 (dollars in thousands):

Edgar Filing: BRUKER BIOSCIENCES CORP - Form 10-Q

| | 2005 | | 2004 | |
|-----------------------------------|-----------------------------|--|-----------------------------|--|
| | Research and Development | Percentage of Segment Product and Service Revenue | Research and Development | Percentage of Segment Product and Service Revenue |
| Bruker Daltonics | \$ 21,101 | 18.3% | \$ 21,507 | 20.2% |
| Bruker AXS | 10,850 | 10.8% | 9,584 | 10.5% |
| Total Research and Development | \$ 31,951 | 14.9% | \$ 31,091 | 15.7% |

Bruker Daltonics research and development expense for the nine months ended September 30, 2005 decreased to \$21.1 million, or 18.3% of product and service revenue, from \$21.5 million, or 20.2% of product and service revenue for the comparable period in 2004. The decrease in research and development expenses is primarily attributable to benefits realized from cost control initiatives announced during the second half of 2004 and to a decrease in material purchases during the nine months ended September 30, 2005 compared to the comparable period in 2004.

Bruker AXS research and development expense for the nine months ended September 30, 2005 increased to \$10.9 million, or 10.8% of product and service revenue, from \$9.6 million, or 10.5% of product and service revenue for the comparable period in 2004. The increase in research and development expense as a percentage of product and service revenue is primarily related to the purchase of materials associated with completing a prototype for a potential new product expected to be introduced within the next year.

Interest and Other Income (Expense), Net

Interest and other income (expense), net, during the nine months ended September 30, 2005 was \$1.0 million compared to (\$2.8) million during the comparable period in 2004. During the nine months ended September 30, 2005, the major components within interest and other income (expense), net, were net interest income of \$1.1 million and losses on foreign currency transactions of (\$0.1) million. During the nine months ended September 30, 2004, the major components within interest and other income (expense), net were the write-off an investment in the amount of (\$2.3) million and net interest expense of (\$0.4) million.

Provision for Income Taxes

The income tax provision for the nine months ended September 30, 2005 was \$5.5 million compared to an income tax provision of \$0.4 million for the comparable period in 2004. During the nine months ended September 30, 2005 and 2004, our effective tax rate was approximately 74% and (6%), respectively, and reflects our tax provision for non-U.S. entities only since no benefit was recognized for losses incurred in the U.S. We will maintain a full valuation allowance for our U.S. net operating losses until such evidence exists that it is more likely than not that the loss carry-forward amounts will be utilized to offset U.S. taxable income. Our tax rate may change over time as the amount or mix of income and taxes outside the U.S. changes. Our effective tax rate is calculated using our projected annual pre-tax income or loss and is affected by research and development tax credits, the expected level of other tax benefits, the impact of changes to the valuation allowance as well as changes in the mix of our pre-tax income and losses among jurisdictions with varying statutory tax rates and credits.

Minority Interest in Consolidated Subsidiaries

Minority interest in consolidated subsidiaries for each of the nine months ended September 30, 2005 and 2004 was \$0.1 million. The minority interest in subsidiaries represents the minority shareholders' proportionate share of net income of these subsidiaries for the nine months ended September 30, 2005 and 2004. For the nine months ended September 30, 2005 and 2004, the minority interest relates to our two majority-owned subsidiaries, Incoatec GmbH and Baltic Scientific Instruments Ltd.

LIQUIDITY AND CAPITAL RESOURCES

We currently anticipate that our existing capital resources will meet our operating and investing needs for at least the next twelve months. Cash requirements for periods beyond the next twelve months depend on our profitability, our ability to manage working capital requirements and our growth rate. Historically, we have financed our growth through a combination of debt financings and issuances of common stock. In the future, there can be no assurance that additional financing alternatives will be available to us if required, or if available, will be obtained with terms favorable to us.

During the nine months ended September 30, 2005, net cash provided by operating activities was \$25.6 million compared to net cash used in operating activities of \$10.5 million during the nine months ended September 30, 2004. The increase in cash provided by

Edgar Filing: BRUKER BIOSCIENCES CORP - Form 10-Q

operating activities was primarily attributable to decreases in accounts receivable and inventories and increases in customer deposits.

During the nine months ended September 30, 2005, investing activities used \$2.2 million in cash compared to net cash used in investing activities of \$4.2 million during the nine months ended September 30, 2004. Cash used in investing activities during the nine months ended September 30, 2005 and 2004 was primarily attributable to capital expenditures. During the remainder of 2005, we expect to continue to make modest capital investments, focusing on enhancing the efficiency of our operations and supporting our anticipated continued growth.

During the nine months ended September 30, 2005, financing activities used \$3.1 million of cash compared to providing \$14.7 million of cash during the nine months ended September 30, 2004. The decrease in cash provided by financing activities during the nine months ended September 30, 2005 is attributable to a completion of a public offering of our common stock in April of 2004 which generated net proceeds to the Company of approximately \$14.5 million, and the net repayment of debt totaling \$3.6 million during the nine months ended September 30, 2005.

We have a demand revolving line of credit with Citizens Bank in the United States in the amount of \$2.5 million. The line of credit, which is secured by portions of our inventory, receivables and equipment in the United States, is used to support our working capital requirements and expires in June 2006. As of September 30, 2005, the full amount of our U.S. line of credit was available. We also maintain revolving lines of credit totaling approximately \$33.9 million with various German and Japanese banks. The German and Japanese lines of credit are unsecured. As of September 30, 2005, approximately \$9.5 million was outstanding on our German and Japanese lines of credit.

In addition to our lines of credit, we have both short-term and long-term notes payable with outstanding balances aggregating approximately \$32.8 million as of September 30, 2005. The interest rates on these obligations range from 1.00% to 5.10%. We entered into an interest rate swap to hedge the variability of cash flows related to changes in interest rates on borrowings of variable debt obligations and pay a 4.6% fixed rate of interest and receive a variable rate of interest based on the Bond Market Association Municipal Swap Index. The interest rate swap has a notional value of \$2.2 million which decreases in conjunction with the IRB payment schedule until the interest rate swap and IRB agreements terminate in December 2013.

The following table summarizes maturities for our significant financial obligations as of September 30, 2005 (in thousands):

| Contractual Obligations | Total | Less than 1 year | 1-3 years | 4-5 years | More than 5 years |
|--------------------------------------|------------------|---------------------|--------------|--------------|----------------------|
| Short-term borrowings | \$ 10,960 | \$ 10,960 | | | |
| Pension | 8,214 | 4 | 4 | 8 | 8,198 |
| Total contractual obligations | \$ 19,174 | \$ 10,964 | \$ 4 | \$ 8 | \$ 8,198 |

As of September 30, 2005, the Company also has outstanding long-term debt totaling \$21.8 million. In connection with some of our outstanding debt, we are required to maintain certain financial ratios and meet other financial criteria. Additionally, we are subject to a variety of restrictive covenants that require bank consent if not met. As of September 30, 2005, the latest measurement date, we were not in compliance with the required debt service coverage ratio associated with our industrial revenue bonds from the State of Wisconsin. On October 24, 2005, the Company received from the holder of the debt a limited waiver for the quarterly measurement period ending September 30, 2005.

Recent Accounting Pronouncements

Edgar Filing: BRUKER BIOSCIENCES CORP - Form 10-Q

In May 2005, the FASB issued SFAS No. 154, *Accounting Changes and Error Corrections*, a replacement of APB Opinion No. 20, *Accounting Changes* and FASB Statement No. 3, *Reporting Accounting Changes in Interim Financial Statements* (SFAS 154). SFAS 154 provides guidance on the accounting for and reporting of accounting changes and error corrections. It establishes, unless impracticable, retrospective application as the required method for reporting a change in accounting principle in the absence of explicit transition requirements specific to the newly adopted accounting principle. SFAS 154 also provides guidance for determining whether retrospective application of a change in accounting principle is impracticable and for reporting a change when retrospective application is impracticable. The provisions of this Statement are effective for accounting changes and corrections of errors made in fiscal periods beginning after December 15, 2005. The adoption of the provisions of SFAS 154 is not expected to have a material impact on the Company's financial position or results of operations.

In December 2004, the FASB issued SFAS No. 123 (Revised 2004) *Share-Based Payment* (SFAS No. 123R) that addresses

the accounting for share-based payment transactions in which a Company receives employee services in exchange for (a) equity instruments of the Company or (b) liabilities that are based on the fair value of the Company's equity instruments or that may be settled by the issuance of such equity instruments. SFAS No. 123R addresses all forms of share-based payment awards, including shares issued under employee stock purchase plans, stock options, restricted stock and stock appreciation rights. SFAS No. 123R eliminates the ability to account for share-based compensation transactions using APB Opinion No. 25, Accounting for Stock Issued to Employees, that was provided in SFAS 123 as originally issued. As permitted by SFAS No. 123R, the Company currently accounts for share-based payments to employees using the intrinsic value method allowed under APB Opinion 25 and, as such, generally recognizes no compensation cost for employee stock options. Accordingly, the adoption of SFAS No. 123R fair value method will have a significant impact the Company's results of operations, although it will have no impact on our overall financial position. The impact of adoption of SFAS No. 123R cannot be predicted at this time because it will depend on levels of share-based payments granted in the future. However, had we adopted SFAS No. 123R in prior periods, the impact would have approximated the amounts calculated using SFAS No. 123 as described in the disclosure of pro forma net loss and net loss per share in Note 3 to our consolidated financial statements.

ITEM 3: Quantitative and Qualitative Disclosures About Market Risk

We are potentially exposed to market risk associated with changes in foreign exchange and interest rates for which we selectively use financial instruments to reduce related market risks. An instrument is treated as a hedge if it is effective in offsetting the impact of volatility in our underlying exposure. We have also entered into instruments which are not effective derivatives under the requirements of SFAS No. 133, and therefore such instruments are not designated as hedges. All transactions are authorized and executed pursuant to our policies and procedures. Analytical techniques used to manage and monitor foreign exchange and interest rate risk include market valuations and sensitivity analysis.

The Company regularly invests excess cash in overnight repurchase agreements and interest-bearing investment-grade securities that we hold for the duration of the term of the respective instrument and are subject to changes in short-term interest rates. The Company believes that the market risk arising from holding these financial instruments is minimal.

The Company's exposure to market risks associated with changes in interest rates relates primarily to the increase or decrease in the amount of interest income earned on its investment portfolio. The Company ensures the safety and preservation of invested funds by limiting default risks, market risk and reinvestment risk. The Company mitigates default risk by investing in investment grade securities. Declines in interest rates over time will, however, reduce the Company's interest income.

Impact of Foreign Currencies

We sell products in many countries, and a substantial portion of sales and expenses are denominated in foreign currencies, principally in the Euro. During the nine months ended September 30, 2005, the U.S. dollar was weaker than the Euro compared to the nine months ended September 30, 2004. This increased our consolidated revenue growth by \$4.8 million, or approximately 2.5%, expressed in U.S. dollars.

While we may from time to time hedge specifically identified cash flows in foreign currencies using forward contracts, this foreign currency activity historically has not been material. The maturities of the forward exchange contracts generally coincide with the settlement dates of the related transactions. Realized and unrealized gains and losses on these contracts are recognized in the same period as gains and losses on the hedged items. As of September 30, 2005, there were no foreign currency forward contracts outstanding.

Realized foreign exchange gains (losses) were approximately \$0.1 million and (\$0.2) million for the three months ended September 30, 2005 and 2004, respectively and approximately (\$0.2) million and \$0.0 million for the nine months ended September 30, 2005 and 2004, respectively. As we continue to expand internationally, we evaluate currency risks and may continue to enter into foreign exchange contracts from time to time to mitigate foreign currency exposure.

We have entered into foreign-denominated debt obligations. The currency effects of the debt obligations are reflected in interest and other income (expense), net, on the consolidated statement of operations. We also have foreign-denominated intercompany borrowing arrangements with our Bruker Daltonik GmbH subsidiary in Germany, our Bruker AXS GmbH subsidiary in Germany and our Bruker Nonius subsidiary in the Netherlands that affected accumulated other comprehensive income (loss). A 10% increase or decrease of the respective foreign exchange rate with our Bruker Daltonik GmbH subsidiary in Germany would result in a change in accumulated other comprehensive income (loss) of approximately \$1.0 million. A 10% increase or decrease of the respective foreign exchange rate with our Bruker Nonius subsidiary in the Netherlands would result in a change in accumulated other comprehensive income (loss) of approximately \$1.0 million or \$(0.9) million, respectively. A 10% increase or decrease of the respective foreign exchange rate with our

Brucker AXS GmbH subsidiary in Germany would result in a translation gain (loss) of approximately \$0.7 million or \$(0.5) million, respectively.

Impact of Interest Rates

Our exposure related to adverse movements in interest rates is derived primarily from outstanding floating rate debt instruments that are indexed to short-term market rates and cash equivalents. Our objective in managing our exposure to interest rates is to decrease the volatility that changes in interest rates might have on our earnings and cash flows. To achieve this objective, we use a fixed rate agreement to adjust a portion of our debt that is subject to variable interest rates.

In the U.S., we have entered into an interest rate swap arrangement to limit the interest rate exposure on our \$2.2 million industrial revenue bond to a fixed rate of 4.6%. We pay a 4.6% fixed rate of interest and receive a variable rate of interest based on the Bond Market Association Municipal Swap Index on a \$2.2 million notional amount. Net interest payments or receipts are recorded as adjustments to interest expense. In addition, the instrument is recorded at fair market value on our balance sheet, and changes in the fair market value are recorded in current earnings. As of September 30, 2005, the fair value of the instrument was approximately \$0.1 million, net of tax, and is recorded as a liability on the balance sheet.

In April 2002, we entered into two derivative financial instruments: a cross currency interest rate swap and an interest rate swap. The cross currency interest rate swap of 2 million Euro secures a fixed interest rate of 1.75% per annum until January 4, 2012. The interest rate swap of 3 million Euro reduces the 6-month EURIBOR rate by 1.80% per annum until January 4, 2007. We entered into the financial instruments to manage our exposure to interest rates and foreign exchange risk. During the year ended December 31, 1999, we entered into three financial instruments: an interest rate cap, an interest rate swap and a cross currency interest rate swap. By entering into these financial instruments, we obtained the right to borrow money at lower rates of interest. We continue to hold these financial instruments until we elect to exercise the options to borrow the money. Until the instruments become an effective hedge, the instruments are considered speculative and are marked-to-market through interest and other income (expense), net, in the consolidated statement of operations. The change in the fair value of these instruments was not material for any period presented. As of September 30, 2005, the fair value of these instruments was approximately \$0.2 million, net of tax, and is recorded as a liability on the balance sheet.

A 10% increase or decrease in the average cost of our variable rate debt would not result in a material change in pre-tax interest expense.

Inflation

We do not believe inflation had a material impact on our business or operating results during the periods presented.

ITEM 4: Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

The term "disclosure controls and procedures" is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the "Exchange Act"). The rules refer to the controls and other procedures designed to ensure that information required to be disclosed in reports that the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified. The Company's management, including the Company's chief executive officer and chief financial officer, performed an evaluation of the effectiveness of the design and operation of the Company's disclosure controls and procedures as of September 30, 2005. Based on that evaluation and due to the material weaknesses in our internal control over financial reporting identified and disclosed in our Annual Report on Form 10-K, for the year ended December 31, 2004, we concluded that the Company's disclosure controls and procedures were not effective as of September 30, 2005.

(b) Changes in Internal Controls over Financial Reporting

In our Annual Report on Form 10-K, for the year ended December 31, 2004, we identified and disclosed material weaknesses in our internal control over financial reporting at one significant subsidiary whose operations and financial condition are significant to the Company's consolidated financial statements. In response to these material weaknesses identified, we have taken steps to strengthen our internal controls over financial reporting. These steps have included the following:

We evaluated and continue to evaluate the roles and functions within the significant subsidiary's accounting department and added additional resources to support the controls surrounding inventory costing and the financial statement close process. Temporary staff had been used to perform additional procedures while management evaluated resources and systems.

Permanent personnel resources were also in place by the end of the third quarter of 2005. The additional resources together with the current accounting staff will improve existing policies and procedures to enable proper financial reporting.

In addition to augmenting the Company's accounting personnel, management's long-term goal is to automate and establish certain preventative controls through the implementation of a fully integrated Materials Resource Planning (MRP) system. Management selected an MRP system during the third quarter of 2005 and expects the implementation to be completed during the first half of 2006.

Management believes that the above measures, when fully implemented, will address the material weaknesses described in our Annual Report on Form 10-K, for the year ended December 31, 2004, in the near and long-term. The Audit Committee and management will continue to monitor the effectiveness of our internal controls and procedures on an ongoing basis and will take further action, as appropriate.

During the nine month period ended September 30, 2005, there were no other significant changes in the Company's internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting. The Company will continue to include reports on its progress in these areas in its quarterly filings with the SEC.

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the control system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.

The statements contained in Exhibits 31.1 and 31.2 should be considered in light of, and read together with, the information set forth in this Item 4.

PART II OTHER INFORMATION

ITEM 1: Legal Proceedings

General

The Company may, from time to time, be involved in legal proceedings in the ordinary course of business. The Company is not currently involved in any pending legal proceedings that, either individually or taken as a whole, are reasonably likely in management's judgment to materially harm our business, prospects, results of operations or financial condition, nor have any such legal proceedings been threatened.

ITEM 2: Unregistered Sales of Equity Securities and Use of Proceeds

None.

ITEM 3: Defaults Upon Senior Securities

None.

ITEM 4: Submission of Matters to a Vote of Security Holders

None.

ITEM 5: Other Information

None.

ITEM 6: Exhibits

Edgar Filing: BRUKER BIOSCIENCES CORP - Form 10-Q

- +2.2 Purchase and Transfer Agreement for Shares in Röntec AG dated October 10, 2005 between Bruker AXS GmbH and the Sellers as defined therein (1).
- +2.3 Asset Purchase Agreement dated October 21, 2005 between Bruker AXS Inc., Princeton Gamma-Tech Instruments, Inc., Princeton Gamma-Tech (UK), Ltd., Finn-Partners, Inc. and Third Letter Corporation (1).
- 31.1 Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (1).
- 31.2 Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (1).
- 32.1 Certification by Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (2).

(1) Filed herewith

(2) Furnished herewith

(+) Confidential treatment requested as to certain portions, which portions have been omitted and filed separately with the Commission.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

BRUKER BIOSCIENCES CORPORATION

Date: November 9, 2005

By: */s/ Frank H. Laukien, Ph.D.*
Frank H. Laukien, Ph.D.
*President, Chairman, Chief Executive Officer, and
Director
(Principal Executive Officer)*

Date: November 9, 2005

By: */s/ William J. Knight*
William J. Knight
*Chief Financial Officer
(Principal Financial and Accounting Officer)*